» Articles » PMID: 25613093

Early Phase Glucagon and Insulin Secretory Abnormalities, but Not Incretin Secretion, Are Similarly Responsible for Hyperglycemia After Ingestion of Nutrients

Abstract

Aims: Hypersecretion of glucagon and reduced insulin secretion both contribute to hyperglycemia in type 2 diabetes (T2DM). However, the relative contributions of impaired glucagon and insulin secretions in glucose excursions at the various stages of T2DM development remain to be determined.

Methods: The responses of glucagon and insulin as well as those of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were examined before and after ingestion of glucose or mixed meal in Japanese subjects with normal or impaired glucose tolerance (NGT and IGT) and in non-obese, untreated T2DM of short duration.

Results: In OGTT, T2DM showed a rise in glucagon at 0-30 min, unlike NGT and IGT, along with reduced insulin. In MTT, all three groups showed a rise in glucagon at 0-30 min, with that in T2DM being highest, while T2DM showed a significant reduction in insulin. Linear regression analyses revealed that glucose area under the curve (AUC)0-120 min was associated with glucagon-AUC0-30 min and insulin-AUC0-30 min in both OGTT and MTT. Total and biologically intact GIP and GLP-1 levels were similar among the three groups.

Conclusions: Disordered early phase insulin and glucagon secretions but not incretin secretion are involved in hyperglycemia after ingestion of nutrients in T2DM of even a short duration.

Citing Articles

Pathogenesis of type 2 diabetes in Japan and East Asian populations: Basic and clinical explorations.

Seino Y, Yamazaki Y Proc Jpn Acad Ser B Phys Biol Sci. 2025; 101(2):68-74.

PMID: 39924177 PMC: 11893219. DOI: 10.2183/pjab.101.009.


The impact of overseas assignments on metabolic factors: Panasonic cohort study 23.

Murano T, Okada H, Hamaguchi M, Kurogi K, Tatsumi Y, Murata H J Occup Health. 2024; 66(1).

PMID: 39572004 PMC: 11659593. DOI: 10.1093/joccuh/uiae071.


Advances in clinical research on glucagon.

Horie I, Abiru N Diabetol Int. 2024; 15(3):353-361.

PMID: 39101175 PMC: 11291794. DOI: 10.1007/s13340-024-00705-w.


Rise in fasting and dynamic glucagon levels in children and adolescents with obesity is moderate in subjects with impaired fasting glucose but accentuated in subjects with impaired glucose tolerance or type 2 diabetes.

Pixner T, Chaikouskaya T, Lauth W, Zimmermann G, Morwald K, Lischka J Front Endocrinol (Lausanne). 2024; 15:1368570.

PMID: 39027470 PMC: 11254805. DOI: 10.3389/fendo.2024.1368570.


The integrated incretin effect is reduced by both glucose intolerance and obesity in Japanese subjects.

Hamasaki A, Harada N, Muraoka A, Yamane S, Joo E, Suzuki K Front Endocrinol (Lausanne). 2024; 15:1301352.

PMID: 38966210 PMC: 11222327. DOI: 10.3389/fendo.2024.1301352.